August 18, 2020

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549


Abby Adams

Celeste Murphy

Vanessa Robertson

Daniel Gordon



Kymera Therapeutics, Inc.

Acceleration Request for Registration Statement on Form S-1

File No. 333-240264

Dear Ms. Adams,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kymera Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 20, 2020, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Gabriela Morales-Rivera, by facsimile to (617) 801-8858.

If you have any questions regarding this request, please contact Gabriela Morales-Rivera of Goodwin Procter LLP at (617) 570-1329.



/s/ Nello Mainolfi

Nello Mainolfi, Ph.D.
President and Chief Executive Officer



Nello Mainolfi, Ph.D., Kymera Therapeutics, Inc.

Bruce Jacobs, CFA, MBA, Kymera Therapeutics, Inc.

William D. Collins, Esq., Goodwin Procter LLP

Gabriela Morales-Rivera, Esq., Goodwin Procter LLP

[Signature Page to Acceleration Request]